Oliver Weingärtner: What Can Real-World Data Teach Us about Long-Term Treatment Persistence in CP?
Oliver Weingärtner, Professor of Medicine at Friedrich-Schiller University Jena, shared a post on LinkedIn about a recent article by Wolfgang Koenig et al., published in Clinical Research in Cardiology, adding:
“Another Alarming Gap in Cardiovascular Care
What can real-world data teach us about long-term treatment persistence in cardiovascular prevention?
Cardiovascular disease remains the leading cause of death in Germany.
While effective strategies exist to lower LDL cholesterol and reduce cardiovascular risk, a major challenge remains: many patients do not stay on treatment over the long term.
A retrospective cohort study analyzed real-world data from nearly 900,000 patients over 36 months.
The findings highlight an important gap in the patient journey and raise critical questions about how we support patients beyond.
The Persistence Challenge
- A substantial proportion of patients discontinued treatment within the first year.
- Long-term persistence remained low over the 36-month follow-up period.
- Women consistently demonstrated lower persistence rates than men.
The Silver Lining
Among patients who remained on therapy, adherence was generally high, suggesting that once patients stay engaged with treatment, they are often able to follow their prescribed regimen successfully.
The Bigger Picture
The challenge is not only identifying patients at risk and initiating appropriate management.
It is also ensuring ongoing support throughout the patient journey to help patients remain engaged with long-term cardiovascular risk reduction strategies.
Improving persistence may require a combination of patient education, shared decision-making, regular follow-up, and healthcare system interventions that address barriers to long-term treatment.
Every step in the patient journey matters.
From risk identification and diagnosis to long-term management and follow-up, helping patients stay engaged in their care remains a key opportunity to improve cardiovascular outcomes.
How can we better support patients throughout their cardiovascular prevention journey to improve long-term treatment persistence?”
Title: Retrospective real-world analysis of adherence and persistence to lipid-lowering therapy in Germany
Authors: Wolfgang Koenig, Elke S. Lorenz, Lea Beier, Ioanna Gouni-Berthold
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 9, 2026, 22:47Avirup Guha: Early Immune Responses to Androgen Deprivation Therapy and Coronary Plaque Progression
-
Nov 9, 2026, 22:42Angela Forsyth: Joining Novo Nordisk as Medical Liaison for the Ohio Valley Region
-
Nov 9, 2026, 22:36Vladimir Otasevic: Presenting Thromboprophylaxis and Treatment of VTE in Patients With Malignancy
-
Nov 9, 2026, 22:28Dragoș Claudiu Popescu: Corticosteroid Exposure and Thrombotic Risk in ITP
-
Nov 9, 2026, 22:20Cedric Ghevaert: How RNA Processing Defects Affect Megakaryocytes in TAR Syndrome
-
Nov 9, 2026, 22:07Todd C. Villines: PARAMOUNT Shows Benefits of Coronary Plaque-Based Care in Stable Symptomatic Patients
-
Nov 9, 2026, 22:06Maxima Mendez: Complete Results of the Pelacarsen Cardiovascular Outcomes Study at AHA 2026
-
Nov 9, 2026, 22:04The Role of the Spleen in Inflammation During Acute Plasmodium Vivax Malaria – American Journal of Hematology
-
Nov 9, 2026, 21:52Behnood Bikdeli: Honored to Share the Stage at AHA 2026 to Discuss Grant Funding